First ‘Make in India' 1-MW green hydrogen plant commissioned in Gujarat
Deendayal Port Authority
(DPA) on Thursday commissioned the country's first 'Make in India' one megawatt (MW) green hydrogen plant, at Kandla. This is the first phase of a planned 10MW facility and is the first such development at an Indian port.
Union shipping minister Sarbananda Sonowal inaugurated the plant, calling it a "new benchmark" in the execution of green hydrogen projects. "DPA has demonstrated a shining example of speed, scale and skill," he said.
The plant was set up in four months and is fully indigenous. The electrolyzer used to produce the hydrogen is made in India, and the entire project was led by Indian engineers. The green hydrogen generated will initially power 11 buses and street lighting within the port. Over time, DPA aims to use it to fuel all the resources of the port.
DPA chairman S K Singh told TOI, "Another 5MW will be added by the end of this fiscal year, with the full 10MW facility expected to be operational by the middle of the next fiscal year."
"DPA becomes the first port in India to operationalize a Make-In-India green hydrogen facility of this scale, capable of producing approximately 140 metric tonnes of green hydrogen annually. This breakthrough marks a pivotal step in
maritime decarbonization
, enhancing India's global leadership in sustainable port operations," DPA said in a statement. Green hydrogen has many applications such as fuel for power plants, vehicles, tugs and vessels.
The foundation stone for the plant was laid by Prime Minister Narendra Modi on May 26 during his visit to Bhuj.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
3 minutes ago
- Economic Times
Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO
Mr. Krishnakumar Vaidyanathan, Executive Director & Chief Operating Officer Eris Lifesciences looks to leverage its experience in integrated diabetes portfolio to take a lead among the first wave of generic semaglutide anti-diabetic and weight-loss drugs to hit the market early next year, a top official said. The company is looking at a 'good' share of the market, Krishnakumar Vaidyanathan, executive director and chief operating officer of Eris Lifesciences, told ET in an interaction. Semaglutide is the active ingredient in Novo Nordisk's blockbuster drugs Wegovy and Ozempic. Its patent in India will expire in March 2026. 'We are gearing up to be among the first to enter the market post loss of exclusivity,' Vaidyanathan said. 'We expect the overall market for GLP-1 at the end of the first 12 months (after the loss of exclusivity) to be at least 10 million units… And we expect to get a good share of the market.' Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Eris Lifesciences' existing diabetes portfolio includes orals, insulin and GLP-1 in the form of liraglutide. Its network of field representatives, patient connect and service platform in this space gives the firm an advantage over others, Vaidyanathan said. 'We do this day in and day out because of insulin. That gives us the confidence that we'll be able to step this up for GLP-1 as well.'Globally, the GLP-1 market is dominated by Eli Lilly and Novo Nordisk, which are also the two biggest insulin companies in the world. 'Being successful and big in the insulin market provides a huge tailwind when it comes to selling GLPs,' Vaidyanathan said. 'We have combined service with technology and product to create a winning combination in insulin and GLP therapy entry is not any different, which also requires a lot of patient education over and above the service on using the pens,' he said. 'We have an integrated diabetes portfolio because we currently sell GLP-1 in the form of liraglutide.' Dr Reddy's Labs, Sun Pharmaceutical Industries, Cipla, Mankind Pharma, Torrent Pharmaceuticals, and Zydus Lifesciences are also among Indian drugmakers readying to launch generic semaglutide next year. Eris Lifesciences launched liraglutide, a once-a-week GLP-1 product, last September. 'We have taken very good market shares in all the other LOE (loss of exclusivity) opportunities that we have seen in diabetes,' Vaidyanathan said. 'We have taken market ranks of 1 to 5 in each one without exception – vildagliptin, sitagliptin, linagliptin, dapagliflozin and empagliflozin. That gives us the confidence that we should be getting a fair share of the market.' Vishal Manchanda, pharma analyst at brokerage Systematix Group, said its full portfolio of anti-diabetes drugs to offer to diabetologist, spanning all oral and injectable options, should give Eris Lifesciences 'a strong positioning in a market where the large pharma majors like Sun, Lupin, Dr Reddy's, Cipla, Mankind and Zydus come in with their dominant brand presence.'
Hans India
6 minutes ago
- Hans India
Vedanta continues winning street confidence: Brokerages forecast strong earnings ahead
New Delhi: Major global and Indian brokerages remain optimistic on Vedanta Ltd's performance for FY26, citing stronger LME pricing trends, cost discipline, deleveraging, and a resilient aluminium business among the key growth drivers. These firms have also taken note of the several growth projects scheduled for commissioning or completion in the next few quarters. JP Morgan noted that Vedanta's first quarter consolidated EBITDA was largely in line with estimates, with key segments such as aluminium, oil and gas, and power faring better than its expectations, leading to an overall segmental EBITDA beat. On the earnings trajectory for the current and next fiscal, the firm expects various ongoing initiatives at Vedanta to aid growth. "Vedanta's capacity expansion journey in the aluminium business as well as vertical integration should bring cost advantages. LME prices have also bottomed out and should continue to move higher into FY26-27, likely aiding earnings growth." Echoing similar views on LME prices and its potential benefit, Citi Research cited that Vedanta's parent (Vedanta Resources) leverage is at comfortable levels. It listed potential upside in medium-term aluminium LME prices, lower cost, and the demerger as another positive for Vedanta, while adding that aluminium globally has a limited supply growth. Mumbai-based Nuvama Institutional Equities expects Vedanta to deliver quarter-on-quarter EBITDA growth in Q2. "Q2FY26 EBITDA is likely to increase 10 per cent-plus quarter-on-quarter on the back of higher prices and lower aluminium cost of production. Major aluminium projects are likely to be commissioned in Q2FY26. We reckon net debt/EBITDA ex-Hindustan Zinc shall fall to 1.7x by FY26-end, compared to 2.7x in FY25. Demerger of the business is likely to be concluded in Q4FY26," the firm said in its report. The brokerage expects Vedanta's all major projects except coal blocks to be likely commissioned in the current fiscal, providing volume growth and cost reduction visibility for the company. UK-based Investec stated in its post-earnings report that Vedanta is a key beneficiary of depreciation in the Indian Rupee. Other near-term positives listed by the firm include declining alumina prices and the company offering attractive yields. The firm has retained its buy recommendation on Vedanta. Research firms like Kotak Institutional Equities and IIFL have cited factors like cost efficiencies and deleveraging at both Vedanta Ltd and its parent Vedanta Resources as beneficial factors. Vedanta's adjusted profit after tax jumped 13 per cent year-on-year to Rs 5,000 crore. The company clocked its highest-ever first-quarter EBITDA of Rs 10,746 crore, which was up 5 per cent year-on-year.
New Indian Express
6 minutes ago
- New Indian Express
Centre blocks debate on Bihar electoral roll revision, cites EC autonomy; Opposition cries foul
NEW DELHI: The Union government has signaled its unwillingness to allow a debate on the Special Intensive Revision (SIR) of electoral rolls in Bihar, with Rajya Sabha Deputy Chairman Harivansh invoking a 1988 ruling by former Lok Sabha Speaker Balram Jakhar to reject the Opposition's demand. On Tuesday, Harivansh cited Jakhar's December 1988 decision, which barred parliamentary discussion on the functioning or decisions of the Election Commission (EC), stating that the autonomous body's actions cannot be scrutinized in the House. 'You know that I cannot comment upon the actions and decisions of the EC, which is an autonomous body. Never before have I done it, nor will I do it now. Unless you amend the Constitution and bring the EC under parliamentary purview, we cannot discuss its decisions,' Harivansh said, quoting Jakhar's ruling. The Deputy Chairman's remarks came as he dismissed 34 notices submitted by Opposition MPs, most seeking the suspension of business under Rule 267 to urgently debate the SIR in Bihar and other states. Harivansh cited procedural flaws, including incorrect formatting, the sub judice nature of some matters, and the absence of precedent for such discussions. He expressed concern over the frequent misuse of Rule 267, meant for 'rarest of rare' cases, noting that most notices lacked proper citations or pertained to issues outside Parliament's jurisdiction. 'Despite clear rules, some members are using Rule 267 casually, disrupting proceedings when their notices are disallowed,' he said. Highlighting historical data, Harivansh pointed out that very few such notices had been accepted—none between 2000–2004, only four from 2004–2009, one out of 491 during 2009–2014, and just six out of 3,152 between 2014 and the 2025 Budget Session.
